The Anti-Diabetes Drugs market in the Eurasian Economic Union (EAEU) has been experiencing an upward trend in recent years.
Customer preferences: One of the main customer preferences in the EAEU is for oral anti-diabetes drugs. Patients in the region tend to prefer these drugs over injectables due to their ease of use and convenience. Additionally, there is a growing trend towards the use of combination therapies, where multiple drugs are used in combination to treat diabetes.
Trends in the market: There has been a significant increase in the prevalence of diabetes in the EAEU, which has been driving the growth of the anti-diabetes drugs market. This increase can be attributed to a variety of factors, including changes in diet and lifestyle, as well as an aging population. As a result, there has been a growing demand for anti-diabetes drugs in the region. Another trend in the market is the increasing availability of generic anti-diabetes drugs. This has led to increased competition among drug manufacturers, which has resulted in lower prices for consumers. Additionally, there has been a shift towards the use of newer, more expensive drugs, such as SGLT-2 inhibitors and GLP-1 receptor agonists, which have been shown to be more effective in treating diabetes.
Local special circumstances: One of the main challenges in the EAEU is the lack of access to healthcare in certain regions. This has led to a significant number of undiagnosed cases of diabetes, which has contributed to the high prevalence of the disease in the region. Additionally, there are significant differences in healthcare systems and regulations among the member states of the EAEU, which can make it difficult for drug manufacturers to navigate the market.
Underlying macroeconomic factors: The economic growth in the EAEU has been relatively stable in recent years, which has contributed to the growth of the anti-diabetes drugs market. Additionally, there has been a growing middle class in the region, which has led to increased demand for healthcare services. However, there are significant differences in economic development among the member states of the EAEU, which can impact the availability and affordability of anti-diabetes drugs in certain regions.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
